Hi team MSB
Looks like the monoclonal antibody Gohibic, which targets inflammation in COVID ARDS, just got an EAU for hospitalised COVID patients. This is what we were trying to achieve for Rem-L.
I take some comfort in this decision (even though it seems right now monoclonal antibodies look like our biggest competitors):
1. The FDA still sees COVID as a global emergency. Tick.
2. Our next clinical trial with Vanderbelt is targeting all cause ARDS (i.e. not just COVID ARDS).
3. IMO Remestemcel-L has a much superior safety profile compared to monoclonals when targeting inflammation.
https://www.medscape.com/viewarticle/990441?ecd=wnl_recnlnew5_ous_230406_MSCPEDIT_&uac=457971MR&impID=5312528
Next I found this on Gohibic's Adverse Effects. IMO not so pretty (like Ruxolitinib's side effect profile for GVHD). Rem-L will most likely have a definite advantage in terms of safety if approved IMO.
https://reference.medscape.com/drug/gohibic-vilobelimab-4000305#4
and Warnings:
https://reference.medscape.com/drug/gohibic-vilobelimab-4000305#ANyAANNow fingers crossed for a positive (and hopefully early) GVHD decision; and equally as important a favourable CHF meeting with the words AA mentioned. Both likely IMO and not long to go
- Forums
- ASX - By Stock
- Cell Therapy News/Articles
Hi team MSBLooks like the monoclonal antibody Gohibic, which...
-
- There are more pages in this discussion • 2,101 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B |
Open | High | Low | Value | Volume |
99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 99.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.5¢ | 18069 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 0.990 |
2 | 32880 | 0.985 |
4 | 71034 | 0.980 |
2 | 3059 | 0.975 |
7 | 145890 | 0.970 |
Price($) | Vol. | No. |
---|---|---|
0.995 | 1132 | 1 |
1.000 | 9500 | 3 |
1.005 | 35000 | 1 |
1.010 | 58113 | 4 |
1.015 | 46100 | 3 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online